Press Release

8th September, 2026 The Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Bandra East, Mumbai 400 001. Mumbai 400 051. Scrip Code: 539523 Scrip Symbol: ALKEM Sub: Press Release – Alkem Laboratories Limited launches Renocia Exo™, India’s first patented Ginsenoside Exosome-based hair growth serum Dear Sir(s)/ Madam, This is to inform you that Alkem Laboratories Limited (the “Company”) today announced the launch of Renocia Exo™, a next-generation hair regeneration therapy developed to support the health and vitality of the hair follicle through a comprehensive scientific approach. A press release in this regard is enclosed herewith. Request you to kindly take the same on record. Sincerely, For Alkem Laboratories Limited Manish Narang President – Legal, Company Secretary & Compliance Officer Press Release Alkem launches Renocia Exo™, India’s first patented Ginsenoside Exosome-based hair growth serum Inspired by regenerative dermatology, Renocia Exo™ offers a new multi- targeted approach to hair loss management by supporting the biology of the hair follicle-not just hair growth. The formulation integrates Ginsenoside phyto-exosomes, biomimetic peptides, copper peptides and stem cell-supportive actives to support follicular vitality, scalp health and the natural hair growth cycle. Mumbai, 8th September 2026: Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM, “Alkem” and its subsidiaries) today announced the launch of Renocia Exo™, a next-generation hair regeneration therapy developed to support the health and vitality of the hair follicle through a comprehensive scientific approach. Hair loss has emerged as one of India's fastest-growing dermatological concerns, affecting not only ageing adults but also an increasing number of younger individuals due to genetics, lifestyle changes, environmental stressors and evolving health patterns. While treatment options have expanded over the years, many continue to focus on a limited aspect of the hair growth cycle, even though hair loss is now understood to be driven by a complex interplay of biological mechanisms. Commenting on the launch, Sandeep Singh, Managing Director, Alkem, said, “The science of hair restoration has evolved significantly over the last decade, and so has our understanding of what drives progressive hair thinning. It is influenced by multiple biological processes, including follicular miniaturization, altered cellular signalling, oxidative stress, inflammation, and changes within the follicular microenvironment. This evolving understanding calls for equally evolved therapeutic solutions. With Renocia Exo™, we bring together multiple regenerative technologies to support the biology of the hair follicle in a single daily therapy.” Unlike conventional topical approaches that primarily focus on stimulating visible hair growth, Renocia Exo™ has been developed to support several interconnected biological processes associated with healthy hair follicle function. The formulation also focuses on supporting multiple signalling pathways involved in hair follicle activity while promoting a favourable environment for healthier, stronger hair over time. Its lightweight, cosmetically elegant composition is free from alcohol, sulphates, silicones parabens and mineral oil, making it suitable for regular use as part of dermatologist-guided hair loss management. With the launch of Renocia Exo™, Alkem continues to strengthen its dermatology portfolio by translating emerging scientific insights into practical therapeutic innovations that address evolving patient needs. About Alkem: Alkem Laboratories Ltd. is a leading Indian pharmaceutical company with a legacy of 53 years in providing high-quality medicines to patients. It is the sixth-largest pharmaceutical company in the Indian market with a dominant position in the therapy areas of anti-infectives, gastrointestinal, pain management drugs and supplements. It also has a growing portfolio of products in chronic therapies such as diabetes, neurology, cardiology, dermatology and urology. It has 20 state-of-the-art manufacturing facilities and cutting-edge research and development (R&D) centres across India and the US to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has a meaningful presence in the US, Latin America, Australia and several Asian countries. “Inspiring Healthier Lives” is at the core of the values and culture of the organisation and reinforces its steadfast commitment to global health improvement. For more information, please visit www.alkemlabs.com and follow us on LinkedIn, Instagram, Facebook. Contacts Media: Investors: Richa Sinari Dishant Doshi alkemcorpcomm@alkem.com dishant.doshi@alkem.com +91-9820184988 +91-8082638391